Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;60(2):256-64.
doi: 10.1111/j.1532-5415.2011.03830.x. Epub 2012 Jan 27.

Serum 25-hydroxyvitamin D, transitions between frailty states, and mortality in older adults: the Invecchiare in Chianti Study

Michelle Shardell  1 , Christopher D'Adamo, Dawn E Alley, Ram R Miller, Gregory E Hicks, Yuri Milaneschi, Richard D Semba, Antonio Cherubini, Stefania Bandinelli, Luigi Ferrucci
Affiliations

Serum 25-hydroxyvitamin D, transitions between frailty states, and mortality in older adults: the Invecchiare in Chianti Study

Michelle Shardell et al. J Am Geriatr Soc. 2012 Feb.

Abstract

Objectives: To assess whether serum 25-hydroxyvitamin D (25(OH)D) concentrations relate to transitions between the states of robustness, prefrailty, and frailty and to mortality in older adults.

Design: The Invecchiare in Chianti (InCHIANTI) Study, a prospective cohort study.

Setting: Tuscany, Italy.

Participants: Adults aged 65 and older (N = 1,155).

Measurements: Serum 25(OH)D concentrations measured at baseline; frailty state (robust, prefrail, frail) assessed at baseline and 3 and 6 years after enrollment; and vital status determined 3 and 6 years after enrollment.

Results: The median (interquartile range) 25(OH)D concentration was 16.0 ng/mL (10.4-25.6 ng/mL; multiply by 2.496 to convert to nmol/L). Prefrail participants with 25(OH)D levels less than 20 ng/mL were 8.9% (95% confidence interval (CI) = 2.5-15.2%) more likely to die, 3.0% (95% CI = -5.6-14.6%) more likely to become frail, and 7.7% (95% CI = -3.5-18.7%) less likely to become robust than prefrail participants with 25(OH)D levels of 20 ng/mL or more. In prefrail participants, each 5-ng/mL decrement of continuous 25(OH)D was associated with 1.46 times higher odds of dying (95% CI = 1.18-2.07) and 1.13 higher odds of incident frailty (95% CI = 0.90-1.39) than with recovery of robustness. Transitions from robustness or frailty were not associated with 25(OH)D levels.

Conclusion: Results provide evidence that prefrailty is an "at risk" state from which older adults with high 25(OH)D levels are more likely to recover than to decline, but high 25(OH)D levels were not associated with recovery from frailty. Thus, 25(OH)D levels should be investigated as a potential therapy to treat prefrailty and prevent further decline.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.

Figures

Figure 1
Figure 1
Standardized Odds Ratios of Frailty Transitions, per 5 ng/mL Lower 25(OH)D Standardized odds ratios and 95% confidence intervals per 5 ng/mL lower 25(OH)D. Arrowheads indicate confidence intervals that extend beyond the figure limits. Standardized for age (years), sex, education (years), season of blood collection, smoking (pack-years), alcohol consumption (drinks/wk), body mass index (kg/m2), Mini-Mental State Examination, Center for Epidemiologic Studies – Depression Scale, comorbidities (congestive heart failure, peripheral arterial disease, hypertension, diabetes, osteoarthritis, renal disease, myocardial infarction, angina, chronic obstructive pulmonary disease), calcium intake (mg/day), and creatinine clearance (mL/min) Model 1: Relationship between 25(OH)D and frailty status without including parathyroid hormone (PTH) in the model as a potential mediator Model 2: Relationship between 25(OH)D and frailty status including parathyroid hormone in the model as a potential mediator; interpreted as the association between 25(OH)D and frailty status if PTH were set to low (<32.4 ng/L).
Figure 2
Figure 2
Standardized Odds Ratios of Transitions of Individual Frailty Criteria, per 5 ng/mL Lower 5(OH)D Standardized odds ratios and 95% confidence intervals per 5 ng/mL lower 25(OH)D. Arrowheads indicate confidence intervals that extend beyond the figure limits. Standardized for age (years), sex, education (years), season of blood collection, smoking (pack-years), alcohol consumption (drinks/wk), body mass index (kg/m2), Mini-Mental State Examination (range: 0–30), Center for Epidemiologic Studies – Depression Scale (range: 0–60), comorbidities (congestive heart failure, peripheral arterial disease, hypertension, diabetes, osteoarthritis, renal disease, myocardial infarction, angina, chronic obstructive pulmonary disease), calcium intake (mg/day), and creatinine clearance (mL/min) Model 1: Relationship between 25(OH)D and frailty status without including parathyroid hormone (PTH) in the model as a potential mediator Model 2: Relationship between 25(OH)D and frailty status including parathyroid hormone in the model as a potential mediator; interpreted as the association between 25(OH)D and frailty status if PTH were set to low (<32.4 ng/L).
See this image and copyright information in PMC

References

    1. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–156. - PubMed
    1. Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: Implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59:255–263. - PubMed
    1. Gill TM, Gahbauer EA, Allore HG, et al. Transitions between frailty states among community-living older persons. Arch Intern Med. 2006;166:418–423. - PubMed
    1. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477–501. - PubMed
    1. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab. 2003;88:5766–5772. - PubMed

Publication types